Amneal Pharmaceuticals vs Teva Pharmaceutical Industries
AMRX and TEVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRX and TEVA compare
Teva Pharmaceutical Industries is the larger company, worth 7.1 times as much as Amneal Pharmaceuticals ($49.4B against $6.9B).
On earnings, Amneal Pharmaceuticals is cheaper: it trades at 51.7× trailing earnings, against 70.7× for Teva Pharmaceutical Industries.
Amneal Pharmaceuticals grew revenue faster over the last twelve months (8.9% versus −15.2% for Teva Pharmaceutical Industries).
Teva Pharmaceutical Industries keeps more of each dollar of sales as profit, with a net margin of 5.0% compared with 4.2% at Amneal Pharmaceuticals.
Amneal Pharmaceuticals scores higher on the StockData Score (12 against 7 for Teva Pharmaceutical Industries), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRX | TEVA |
|---|---|---|
| Size and price | ||
| Market cap | $6.9B | $49.4B |
| Share price | $21.71 | $42.40 |
| Change, 1 year | 89.1% | 76.9% |
| Change, 5 years | 370% | 377% |
| Beta (5Y) | 1.07 | 0.98 |
| Employees | 8,500 | 34K |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 5 (better) | 2 |
| Performance score | 5 (better) | 4 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 51.7× (better) | 70.7× |
| P/S | 2.2× (better) | 3.5× |
| P/B | 13.1× | 6.4× (better) |
| EV/EBITDA | 20.3× | 19.4× (better) |
| P/FCF | 78.6× | 36.7× (better) |
| FCF yield | 1.3% | 2.7% (better) |
| Fair value | $13.08 | $19.87 |
| Margin of safety | −66.0% (better) | −113% |
| Growth | ||
| Revenue growth (TTM) | 8.9% (better) | −15.2% |
| Revenue growth, 5Y average | 8.7% (better) | 0.71% |
| Net income growth (TTM) | 2159% | – |
| EPS growth (TTM) | 2000% | – |
| EPS growth, 5Y average | −18.5% | – |
| Profitability | ||
| Gross margin | 40.2% | 64.4% (better) |
| Operating margin | 15.0% (better) | 11.4% |
| Net margin | 4.2% | 5.0% (better) |
| FCF margin | 2.8% | 9.6% (better) |
| Return on equity | 63.2% (better) | 9.7% |
| Return on invested capital | 16.3% | 23.0% (better) |
| Financial health | ||
| Debt / equity | 5.53 | 0.58 (better) |
| Net debt / EBITDA | 5.81 | 0.33 (better) |
| Current ratio | 1.87 (better) | 0.88 |
| Altman Z-score | 1.89 (better) | 0.86 |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 52.7% | – |
| Held by insiders | 60.7% | 0.43% |
| Insider net buying, 12 months | −$7.7M (better) | −$108M |
| Short interest, % of float | 9.1% | 2.4% |
Go deeper
- AMRX stock overview
- AMRX income statement
- AMRX valuation and score
- TEVA stock overview
- TEVA income statement
- TEVA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.